Tracking a promising drug for people with chronic hives
NCT ID NCT07316114
Summary
This study aims to understand how well the drug dupilumab works for people with chronic spontaneous urticaria (CSU), also known as chronic hives, in everyday life. It will follow 400 patients in the U.S. for two years, collecting information from their medical records and their own reports on symptoms, quality of life, and side effects. The goal is to see how effective and safe the treatment is over a long period outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virtual Research Coordination Center
RECRUITINGWilmington, North Carolina, 28401-3331, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.